TY - JOUR
T1 - Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research
T2 - a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
AU - Mulatero, Paolo
AU - Sechi, Leonardo A.
AU - Williams, Tracy Ann
AU - Lenders, Jacques W.M.
AU - Reincke, Martin
AU - Satoh, Fumitoshi
AU - Januszewicz, Andrzej
AU - Naruse, Mitsuhide
AU - Doumas, Michael
AU - Veglio, Franco
AU - Wu, Vin Cent
AU - Widimsky, Jiri
PY - 2020/10/1
Y1 - 2020/10/1
N2 - : Primary aldosteronism is a frequent cause of secondary hypertension requiring a specific pharmacological treatment with mineralocorticoid receptor antagonist or with unilateral adrenalectomy. These treatments have shown to reduce the excess of cardiovascular risk characteristically associated with this disease. In part I of this consensus, we discussed the procedures for the diagnosis of primary aldosteronism. In the present part II, we address the strategies for the differential diagnosis of primary aldosteronism subtypes and therapy. We also discuss the evaluation of outcomes and provide suggestions for follow-up as well as cardiovascular and metabolic complications specifically associated with primary aldosteronism. Finally, we analyse the principal gaps of knowledge and future challenges for research in this field.
AB - : Primary aldosteronism is a frequent cause of secondary hypertension requiring a specific pharmacological treatment with mineralocorticoid receptor antagonist or with unilateral adrenalectomy. These treatments have shown to reduce the excess of cardiovascular risk characteristically associated with this disease. In part I of this consensus, we discussed the procedures for the diagnosis of primary aldosteronism. In the present part II, we address the strategies for the differential diagnosis of primary aldosteronism subtypes and therapy. We also discuss the evaluation of outcomes and provide suggestions for follow-up as well as cardiovascular and metabolic complications specifically associated with primary aldosteronism. Finally, we analyse the principal gaps of knowledge and future challenges for research in this field.
UR - http://www.scopus.com/inward/record.url?scp=85090376081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090376081&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000002520
DO - 10.1097/HJH.0000000000002520
M3 - Article
C2 - 32890265
AN - SCOPUS:85090376081
VL - 38
SP - 1929
EP - 1936
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 10
ER -